FEMARELLE® - a Novel Selective Estrogen Receptor Modulator (SERM) for the Management of Menopause and Bone Loss
Efficacy and safety of DT56a (Femarelle) compared to hormone therapy in Greek postmenopausal women.
Labos G., Trakakis E. et al Efficacy and safety of DT56a (Femarelle) compared to hormone therapy in
Greek postmenopausal women. J Endocrinol. Invest. 2013.
A Prospective Study of DT56a (Femarelle®) for the Treatment of Postmenopausal Vaginal Atrophy
Abstract Book, 22nd Annual Meeting of the North American Menopause Society, Sept. 21-24, 2011.; pg. 55.
DT56a (Femarelle®): a Natural Selective Estrogen Receptor Modulator (SERM)
Journal of Steroid Biochemistry and Molecular Biology 2007; 104:252-258
Pharmacological Doses of the Natural Phyto-SERM DT56a (Femarelle®) Have No Effect on MCF-7 Human Breast Cancer Cell-Line
European Journal of Obstetrics & Gynecology and Reproductive Biology 2007;130(1): 140-141
"DT56a (Femarelle®) Stimulates Gender-Specific Human Cultured Bone Cells In Vitro
Journal of Steroid Biochemistry & Molecular Biology 2006;98(1):90-96
DT56a (Femarelle®/Tofupill) Stimulates Bone Formation in Female Rats
British Journal of Obstetrics & Gynecology 2005; 112(7):981-985
Efficacy and Safety of Standard versus Low Dose of Femarelle® (Tofupill) for the Treatment of Menopausal Symptoms
Journal of Clinical & Experimental Obstetrics & Gynecology 2004; 31(2): 123-126

"DT56a Stimulates Creatine Kinase Specific Activity in Vascular Tissues of Rats
Journal of Endocrinological Investigation 2003;26(10):966-971
Pros and Cons of Plant Estrogens for Menopause
Journal of Steroid Biochemistry and Molecular Biology 2012 December; S. Bedell, et al., The pros and cons of plant estrogens for menopause, J. Steroid Biochem. Mol. Biol. (2013)